Nifty
:
25496.55
Sensex
:
82248.61
14.05 (0.06%)
-27.46 (-0.03%)
Nifty
Sensex
:
:
25496.55
82248.61
14.05 (0.06%)
-27.46 (-0.03%)

Sun Pharmaceutical Industries Ltd.

Pharmaceuticals & Drugs - Global

Rating :
66/99

BSE: 524715 | NSE: SUNPHARMA

NSE BSE
1785.70
26-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  1764.2
  •  1792.2
  •  1760.3
  •  1764.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2076586
  •  3696480667.5
  •  1851.2
  •  1548

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 4,28,185.32
  • 39.23
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 4,20,613.82
  • 0.90%
  • 5.27

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 54.48%
  • 2.03%
  • 5.40%
  • FII
  • DII
  • Others
  • 16.12%
  • 18.76%
  • 3.21%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.46
  • 9.44
  • 6.21

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 6.34
  • 12.24
  • 5.42

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 9.19
  • 30.28
  • 8.70

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 38.76
  • 38.59
  • 37.96

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.10
  • 4.88
  • 5.44

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 19.50
  • 21.60
  • 23.49

Earnings Forecasts:

(Updated: 21-02-2026)
Description
2024
2025
2026
2027
Adj EPS
45.55
50.15
56.12
64.77
P/E Ratio
39.20
35.61
31.82
27.57
Revenue
52041.3
58085.8
64487.5
71388.6
EBITDA
15086.2
16919.4
19001.9
21531.6
Net Income
10929
12060.1
13601
15669.3
ROA
12.31
12.8
13.79
13.44
P/B Ratio
5.93
5.33
4.74
4.20
ROE
16.09
15.78
16.11
16.59
FCFF
12589.5
7789.9
11751.4
13687.1
FCFF Yield
Net Debt
-22625.5
-28490.5
-34962.8
-43961
BVPS
300.99
335.09
376.88
425.47

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
15,520.54
13,675.46
13.49%
14,478.31
13,291.39
8.93%
13,851.40
12,652.75
9.47%
12,958.84
11,982.90
8.14%
Expenses
10,725.97
9,666.44
10.96%
10,381.73
9,480.52
9.51%
9,778.78
9,045.13
8.11%
9,533.99
8,947.75
6.55%
EBITDA
4,794.57
4,009.02
19.59%
4,096.58
3,810.87
7.50%
4,072.62
3,607.62
12.89%
3,424.85
3,035.15
12.84%
EBIDTM
30.89%
29.32%
28.29%
28.67%
29.40%
28.51%
26.43%
25.33%
Other Income
732.76
465.62
57.37%
900.39
482.09
86.77%
693.50
532.55
30.22%
904.11
605.94
49.21%
Interest
78.36
51.51
52.13%
99.86
69.17
44.37%
74.80
61.54
21.55%
49.14
73.57
-33.21%
Depreciation
732.33
630.56
16.14%
729.50
625.91
16.55%
700.55
655.13
6.93%
663.79
650.36
2.07%
PBT
4,227.16
3,476.40
21.60%
4,167.61
3,597.88
15.84%
3,172.77
3,423.50
-7.32%
3,254.35
2,815.52
15.59%
Tax
826.07
558.86
47.81%
1,030.52
567.21
81.68%
870.15
552.25
57.56%
1,093.71
148.93
634.38%
PAT
3,401.09
2,917.54
16.57%
3,137.09
3,030.67
3.51%
2,302.62
2,871.25
-19.80%
2,160.64
2,666.59
-18.97%
PATM
21.91%
21.33%
21.67%
22.80%
16.62%
22.69%
16.67%
22.25%
EPS
14.04
12.10
16.03%
13.00
12.67
2.60%
9.50
11.82
-19.63%
8.96
11.06
-18.99%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
56,809.09
52,578.44
48,496.85
43,885.68
38,654.49
33,498.14
32,837.50
29,065.91
26,415.54
31,308.14
28,108.61
Net Sales Growth
10.09%
8.42%
10.51%
13.53%
15.39%
2.01%
12.98%
10.03%
-15.63%
11.38%
 
Cost Of Goods Sold
11,379.78
10,747.36
10,662.61
10,662.16
10,351.54
8,690.08
9,230.45
7,868.97
7,351.71
8,164.20
6,170.19
Gross Profit
45,429.31
41,831.08
37,834.24
33,223.52
28,302.95
24,808.06
23,607.05
21,196.94
19,063.83
23,143.94
21,938.42
GP Margin
79.97%
79.56%
78.01%
75.70%
73.22%
74.06%
71.89%
72.93%
72.17%
73.92%
78.05%
Total Expenditure
40,420.47
37,492.28
35,747.77
32,298.12
28,772.68
25,030.42
25,863.35
22,792.27
20,880.73
21,625.92
19,950.29
Power & Fuel Cost
-
750.40
760.78
830.05
702.78
595.58
586.18
580.15
527.76
488.46
510.66
% Of Sales
-
1.43%
1.57%
1.89%
1.82%
1.78%
1.79%
2.00%
2.00%
1.56%
1.82%
Employee Cost
-
9,973.12
9,429.06
8,296.03
7,300.83
6,126.18
5,703.57
5,297.62
4,707.99
4,311.85
4,204.06
% Of Sales
-
18.97%
19.44%
18.90%
18.89%
18.29%
17.37%
18.23%
17.82%
13.77%
14.96%
Manufacturing Exp.
-
2,261.24
2,186.62
1,936.77
1,880.71
3,486.62
3,341.64
3,399.20
3,490.23
3,393.59
3,243.54
% Of Sales
-
4.30%
4.51%
4.41%
4.87%
10.41%
10.18%
11.69%
13.21%
10.84%
11.54%
General & Admin Exp.
-
5,646.06
5,252.93
4,256.12
3,270.55
2,224.76
2,431.10
2,033.01
2,112.01
1,834.14
1,891.68
% Of Sales
-
10.74%
10.83%
9.70%
8.46%
6.64%
7.40%
6.99%
8.00%
5.86%
6.73%
Selling & Distn. Exp.
-
6,576.86
5,780.26
5,226.24
4,096.33
3,103.96
3,654.48
2,621.13
1,864.55
2,520.64
2,262.35
% Of Sales
-
12.51%
11.92%
11.91%
10.60%
9.27%
11.13%
9.02%
7.06%
8.05%
8.05%
Miscellaneous Exp.
-
1,537.24
1,675.51
1,090.75
1,169.94
803.24
915.93
992.19
826.48
913.04
2,262.35
% Of Sales
-
2.92%
3.45%
2.49%
3.03%
2.40%
2.79%
3.41%
3.13%
2.92%
5.93%
EBITDA
16,388.62
15,086.16
12,749.08
11,587.56
9,881.81
8,467.72
6,974.15
6,273.64
5,534.81
9,682.22
8,158.32
EBITDA Margin
28.85%
28.69%
26.29%
26.40%
25.56%
25.28%
21.24%
21.58%
20.95%
30.93%
29.02%
Other Income
3,230.76
2,150.57
1,628.24
693.75
1,437.42
859.17
651.59
1,059.44
912.08
1,030.20
658.25
Interest
302.16
231.36
238.47
172.00
127.35
141.43
302.73
555.25
517.57
399.80
523.24
Depreciation
2,826.17
2,575.39
2,556.64
2,529.43
2,143.74
2,079.95
2,052.78
1,753.25
1,499.84
1,264.75
1,037.53
PBT
14,821.89
14,429.98
11,582.21
9,579.88
9,048.14
7,105.51
5,270.23
5,024.58
4,429.48
9,047.87
7,255.80
Tax
3,820.45
2,772.03
1,439.45
847.59
1,075.50
514.69
822.80
600.88
911.04
1,211.57
913.77
Tax Rate
25.78%
20.16%
12.98%
9.01%
24.00%
18.39%
16.42%
15.77%
26.19%
13.39%
13.91%
PAT
11,001.44
10,944.39
9,614.79
8,521.48
3,289.27
2,916.15
3,779.76
2,666.88
2,121.14
6,954.44
4,544.26
PAT before Minority Interest
10,963.79
10,980.10
9,648.44
8,560.84
3,405.82
2,284.68
4,186.79
3,209.32
2,567.94
7,836.30
5,656.86
Minority Interest
-37.65
-35.71
-33.65
-39.36
-116.55
631.47
-407.03
-542.44
-446.80
-881.86
-1,112.60
PAT Margin
19.37%
20.82%
19.83%
19.42%
8.51%
8.71%
11.51%
9.18%
8.03%
22.21%
16.17%
PAT Growth
-4.22%
13.83%
12.83%
159.07%
12.79%
-22.85%
41.73%
25.73%
-69.50%
53.04%
 
EPS
45.85
45.61
40.07
35.52
13.71
12.15
15.75
11.12
8.84
28.99
18.94

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
72,218.02
63,666.75
55,995.38
48,011.22
46,462.78
45,264.45
41,409.06
38,314.11
36,639.67
32,982.48
Share Capital
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
239.93
240.66
Total Reserves
71,978.09
63,426.82
55,755.45
47,771.29
46,222.85
45,024.52
41,169.13
38,074.18
36,397.10
32,736.26
Non-Current Liabilities
-2,987.13
-2,714.34
-1,997.80
-1,316.37
-1,515.17
246.05
76.72
46.43
599.87
2,169.59
Secured Loans
0.00
0.00
0.00
0.00
251.25
257.49
109.47
217.69
185.59
79.31
Unsecured Loans
2.52
1.33
0.00
229.92
646.88
1,771.43
1,413.14
1,554.40
1,250.49
3,030.99
Long Term Provisions
473.80
413.89
342.91
369.07
327.12
511.00
430.39
404.46
1,211.11
1,895.86
Current Liabilities
18,194.21
16,983.77
19,906.38
17,208.45
16,145.63
15,706.43
17,339.62
19,864.32
17,887.02
13,143.96
Trade Payables
6,184.34
5,653.30
5,681.52
4,489.76
3,973.66
3,583.64
4,147.87
4,766.20
4,395.39
3,582.92
Other Current Liabilities
3,254.45
2,716.85
2,603.51
2,926.73
4,965.34
2,535.02
1,761.72
1,875.93
2,673.68
1,134.27
Short Term Borrowings
1,867.11
2,844.36
5,958.26
468.52
2,444.90
5,549.38
8,370.76
7,979.70
6,654.92
5,206.12
Short Term Provisions
6,888.31
5,769.26
5,663.09
9,323.44
4,761.73
4,038.39
3,059.27
5,242.49
4,163.03
3,220.65
Total Liabilities
87,693.03
81,395.37
77,224.05
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,917.42
52,381.28
Net Block
22,586.28
23,248.15
24,065.44
22,665.16
21,552.98
22,846.91
21,836.54
18,852.65
17,675.17
15,872.25
Gross Block
45,949.61
44,320.48
43,099.95
38,707.36
35,578.99
35,115.97
31,687.04
26,948.80
24,466.42
22,180.41
Accumulated Depreciation
23,363.33
21,072.33
19,034.51
16,042.20
14,026.01
12,269.06
9,850.50
8,096.15
6,791.25
6,308.16
Non Current Assets
35,068.56
37,921.02
37,341.33
32,093.59
33,668.21
33,423.01
31,069.75
30,473.12
25,963.77
22,439.98
Capital Work in Progress
6,643.96
5,353.88
4,973.16
1,286.80
1,566.83
1,220.34
1,411.15
2,465.16
2,801.38
2,175.45
Non Current Investment
4,697.70
6,441.23
5,451.73
5,214.65
6,482.39
5,245.75
3,951.81
3,052.25
961.00
1,116.07
Long Term Loans & Adv.
1,016.49
2,784.59
2,757.87
2,880.86
4,061.34
4,104.39
3,848.41
6,052.97
3,844.04
2,322.87
Other Non Current Assets
124.13
93.17
93.13
46.12
4.67
5.62
21.84
50.09
682.18
953.34
Current Assets
52,594.06
43,433.11
39,861.94
34,864.60
30,442.08
31,654.16
31,069.19
31,635.90
32,947.06
29,934.11
Current Investments
13,656.10
8,584.54
9,372.61
7,633.94
3,130.06
4,897.36
3,950.72
4,090.62
230.88
713.81
Inventories
10,243.33
9,868.29
10,513.05
8,925.13
8,997.02
7,874.99
7,885.98
6,880.69
6,832.81
6,422.54
Sundry Debtors
13,046.11
11,249.37
11,438.51
10,484.59
9,061.40
9,421.24
8,884.20
7,815.28
7,202.61
6,775.66
Cash & Bank
11,331.62
10,520.68
5,770.29
5,033.35
6,445.51
6,487.55
7,275.60
9,929.38
15,140.84
13,181.65
Other Current Assets
4,316.90
755.99
745.91
775.01
2,808.09
2,973.02
3,072.69
2,919.93
3,539.92
2,840.45
Short Term Loans & Adv.
3,692.36
2,454.24
2,021.57
2,012.58
1,488.98
1,431.54
1,806.39
2,028.62
2,828.26
2,317.13
Net Current Assets
34,399.85
26,449.34
19,955.56
17,656.15
14,296.45
15,947.73
13,729.57
11,771.58
15,060.04
16,790.15
Total Assets
87,662.62
81,354.13
77,203.27
66,958.19
64,110.29
65,077.17
62,138.94
62,109.02
58,910.83
52,374.09

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
14,072.09
12,134.98
4,959.33
8,984.54
6,170.37
6,554.77
2,196.45
3,907.15
7,082.21
6,685.86
PBT
13,752.13
11,087.89
9,408.43
4,481.32
2,799.37
5,009.59
3,810.20
3,478.98
9,047.87
6,570.63
Adjustment
1,120.36
1,554.40
2,722.56
1,974.95
1,809.85
1,992.54
1,968.66
1,382.22
500.67
1,856.92
Changes in Working Capital
-323.56
1,062.13
-5,661.82
1,559.05
2,564.09
898.55
-2,696.00
-212.31
-409.21
246.77
Cash after chg. in Working capital
14,548.93
13,704.42
6,469.17
8,015.32
7,173.31
7,900.68
3,082.86
4,648.89
9,139.33
8,674.32
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-476.84
-1,569.44
-1,509.84
969.22
-1,002.94
-1,345.91
-886.41
-741.74
-2,057.12
-1,988.46
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-5,306.16
-690.20
-7,943.68
-5,724.74
536.22
-2,588.84
-681.25
-3,370.81
-4,221.60
-4,371.59
Net Fixed Assets
-548.72
-420.26
-573.97
-1,120.95
-8,061.35
-737.44
-543.38
-1,471.92
-1,217.15
2,214.23
Net Investments
19.86
183.27
2,935.63
-11.67
1,824.52
542.39
451.15
978.04
3,038.39
3,504.47
Others
-4,777.30
-453.21
-10,305.34
-4,592.12
6,773.05
-2,393.79
-589.02
-2,876.93
-6,042.84
-10,090.29
Cash from Financing Activity
-7,905.82
-6,710.16
2,376.07
-5,193.46
-5,980.48
-5,715.14
-2,730.52
-1,539.26
-2,285.39
-1,888.53
Net Cash Inflow / Outflow
860.11
4,734.62
-608.28
-1,933.66
726.11
-1,749.21
-1,215.32
-1,002.92
575.22
425.74
Opening Cash & Equivalents
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69
7,183.49
Closing Cash & Equivalent
10,268.77
9,285.65
4,623.73
4,508.25
6,273.03
5,676.61
7,062.30
7,906.45
8,642.36
8,031.69

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
301.00
265.36
233.38
200.11
193.65
188.66
172.59
159.69
152.70
137.03
ROA
12.99%
12.17%
11.88%
5.20%
3.54%
6.58%
5.17%
4.24%
0.00%
11.39%
ROE
16.16%
16.13%
16.46%
7.21%
4.98%
9.66%
8.05%
6.85%
0.00%
19.32%
ROCE
19.89%
17.60%
17.24%
9.28%
5.68%
10.07%
8.68%
8.40%
0.00%
18.64%
Fixed Asset Turnover
1.16
1.11
1.07
1.81
1.74
1.78
1.92
1.99
1.29
1.34
Receivable days
84.33
85.38
91.17
53.09
54.88
56.22
54.10
53.53
83.25
76.12
Inventory Days
69.81
76.70
80.83
48.68
50.10
48.40
47.84
48.88
78.98
77.46
Payable days
201.01
194.01
174.10
149.21
158.71
152.86
77.81
90.19
85.47
75.24
Cash Conversion Cycle
-46.88
-31.93
-2.10
-47.44
-53.73
-48.24
24.13
12.23
76.75
78.34
Total Debt/Equity
0.03
0.04
0.11
0.02
0.08
0.18
0.25
0.27
0.27
0.26
Interest Cover
60.44
47.50
55.70
36.19
20.79
17.55
7.86
7.72
23.63
13.56

Annual Reports:

FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
FY 2019
FY 2018
FY 2017
FY 2016

News Update:


  • Sun Pharma reports 16% rise in Q3 consolidated net profit
    1st Feb 2026, 11:37 AM

    The consolidated total income of the company increased by 13.85% at Rs 16,099.38 crore for Q3FY26

    Read More
  • Sun Pharma Inds. - Quarterly Results
    1st Feb 2026, 00:00 AM

    Read More
  • Sun Pharma gets DCGI’s nod to manufacture, market generic semaglutide injection
    23rd Jan 2026, 10:47 AM

    The company will launch generic semaglutide injection under the brand name -- Noveltreat

    Read More
  • Sun Pharmaceutical’s unit recalls over 17,000 units of antifungal medication in US
    26th Dec 2025, 10:12 AM

    The company is recalling the affected lot due to Failed Impurity/Degradation specifications

    Read More
  • USFDA issues OAI status to Sun Pharmaceutical’s Baska facility
    18th Dec 2025, 10:30 AM

    The company continue to manufacture and supply approved products from the facility to the US market

    Read More
  • Sun Pharmaceutical Industries’ arm gets nod to set up greenfield project
    3rd Dec 2025, 09:40 AM

    Sun Pharma Laboratories has received approval from Board of Directors for an investment of Rs 3,000 crore

    Read More
  • Sun Pharma launches ILUMYA for moderate-to-severe plaque psoriasis
    1st Dec 2025, 11:52 AM

    ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-tosevere plaque psoriasis

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.